SCHEDULE: BlackRock Discloses 5.4% Stake in Aura Biosciences

BlackRock, Inc. has reported a 5.4% beneficial ownership stake in Aura Biosciences Inc., holding 3,336,027 shares of common stock.

Summary

• BlackRock, Inc. filed a Schedule 13G, indicating beneficial ownership in Aura Biosciences Inc.
• BlackRock, Inc. beneficially owns 3,336,027 shares of Aura Biosciences Inc. Common Stock.
• This ownership represents 5.4% of the total outstanding class of securities.
• BlackRock, Inc. holds sole voting power over 3,274,730 shares.
• BlackRock, Inc. holds sole dispositive power over 3,336,027 shares.
• The filing was made by BlackRock, Inc. as a parent holding company or control person.
• The event requiring this filing occurred on September 30, 2025.
• BlackRock Investment Management, LLC is identified as an entity beneficially owning 5% or greater of the outstanding shares.

Sentiment

Score: 7

Explanation: The disclosure of a significant passive stake by a major institutional investor like BlackRock is generally a neutral to slightly positive signal, indicating market liquidity and institutional interest in Aura Biosciences. It does not, however, provide direct operational or financial performance insights.

Positives

• The disclosure of a significant stake by a major institutional investor like BlackRock, Inc. can be interpreted as a vote of confidence in Aura Biosciences Inc.
• Increased institutional ownership may contribute to greater liquidity and stability for Aura Biosciences Inc.'s stock.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Aura Biosciences Inc.'s future performance or strategic direction.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11." (Certification by BlackRock, Inc.)

Industry Context

Institutional investors, such as BlackRock, frequently acquire significant passive stakes in publicly traded companies across various sectors, including biotechnology. Such disclosures are routine for large asset managers who invest on behalf of their clients, reflecting their portfolio allocations rather than specific strategic moves related to the issuer's operations.

Comparison to Industry Standards

• This filing is a standard disclosure of beneficial ownership by a large institutional investor, consistent with SEC regulations for reporting stakes exceeding 5% of a company's outstanding shares. It does not provide specific performance metrics or operational data for direct comparison to industry benchmarks or competitors.

Stakeholder Impact

• Shareholders: The presence of a major institutional investor like BlackRock may enhance market confidence and potentially contribute to stock liquidity.
• Management: Awareness of a significant institutional shareholder may influence future investor relations strategies.

Next Steps

• BlackRock, Inc. will continue to monitor its investment in Aura Biosciences Inc. as part of its ordinary course of business.

Key Dates

Keywords

Aura Biosciences, BlackRock, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Equity Stake, Biotechnology, Financial Reporting